News Headlines Article

Genentech sees promising results from late-stage cancer drug study
San Francisco Business Times

Genentech Inc.’s potential replacement for Rituxan as a treatment for two blood cancers helped patients live longer before their disease progressed again. Genentech, the South San Francisco-based U.S. biotech arm of Swiss drug giant Roche, said the Phase III trial tested its drug, called GA-101, in combination with the chemotherapy agent chlorambucil in previously untreated chronic lymphocytic leukemia patients.